-
Mashup Score: 0
Background The combination of bevacizumab and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) could prolong progression-free survival (PFS) in patients with EGFR-mutant advanced non-small-cell lung cancer (NSCLC). Our study investigated the clinical and molecular factors that affect the efficacy of first-generation EGFR-TKI with or without bevacizumab and identify the…
Source: BMC MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1
A phase III trial evaluated the efficacy and safety of pimitesib in patients with advanced GIST refractory to standard treatments, whose medical requirements remain unmet, presented at the 2021 ASCO Annual Meeting.
Source: HMP Global Learning NetworkCategories: Hem/Oncs, Latest HeadlinesTweet-
Pimitespib Significantly Improves PFS,OS in Patients with Advanced GIST https://t.co/beqc0cLaP9 #pimitesib #gist #tki
-
-
Mashup Score: 0Prevalence and breakdown of EGFR exon 20 driver mutations in routine NHS lung cancer diagnostic testing - 3 year(s) ago
In non-small cell lung cancer (NSCLC), oncogenic driver mutations in epidermal growth factor receptor ( EGFR ) typically occur in exons 18, 19, 20 and 21.1 Until recently, EGFR -driven tumours displaying sensitivity to EGFR tyrosine kinase inhibitors (TKIs) have almost exclusively comprised those with activating mutations in exons 18, 19 and 21, while tumours with primary activating mutations…
Source: Journal of Clinical PathologyCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
#Correspondence "Prevalence and breakdown of #EGFR exon 20 driver mutations in routine NHS #lungcancer diagnostic testing" by Moore et al. #pulmpath #molpath #NGS #TKI đ https://t.co/Cyz1PLvGna https://t.co/xrn7ah8bJQ
-
-
Mashup Score: 15How to Diagnose and Manage QT Prolongation in Cancer Patients: - 3 year(s) ago
Graphical abstract
Source: JACC: CardioOncologyCategories: Cardiac Surgery, Latest HeadlinesTweet-
Learn how to manage QT prolongation in #cancer patients in this handy "How To" guide: https://t.co/NTcc42bYtH #JACCCardioOnc #CardioOnc #OpenAccess #CardioTwitter #MedTwitter #TKI #ECG @onco_cardiology @MDAndersonNews https://t.co/jgwXEk2BV3
-
-
Mashup Score: 8
Abstract Background Ibrutinib is a protein kinase inhibitor that has been widely successful in treating multiple common variations of B-cell cancers. However, an unfortunate side effect of ibrutini…
Source: JACC: CardioOncologyCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Using the @US_FDA reporting system, #Afib is a major problem with many tyrosine kinase inhibitors. Learn more or listen to the podcast here: https://t.co/StT36m5dT6 #JACCCardioOnc #TKI #cardioonc #PKI #EPeeps #OpenAccess #CardioTwitter #MedTwitter @AliciaLundby https://t.co/wTVzIoz47z
-
-
Mashup Score: 6RETROSPECTIVE REAL-WORLD OUTCOMES FOR ALK-REARRANGED LUNG CANCER PATIENTS RECEIVING ALK-RECEPTOR TYROSINE KINASE INHIBITORS - 3 year(s) ago
This study explored the use, safety and efficacy of initial use of an ALK-inhibiting targeted therapy (ALK-TKI) in ALK-rearranged NSCLC patients in a population-based, real-world clinical population within the province of Alberta, Canada.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Gibson et al. reported real-world data from retrospective analysis of #ALK #TKI therapy in pts w/ ALK-rearranged #NSCLC (2014-2019) from a clinical population in Alberta #Canada https://t.co/mcNJXwPNtE @AHS_media @UCalgary @IASLC @OncologyAdvance #JTOCRR #openaccess #LCSM https://t.co/uE3TDRrM4G
-
Gibson et al. reported real-world data from retrospective analysis of #ALK #TKI therapy in pts w/ ALK-rearranged #NSCLC (2014-2019) from a clinical population in Alberta #Canada https://t.co/CKPTxHkjWu @AHS_media @UCalgary @JTOonline @OncologyAdvance #JTOCRR #openaccess #LCSM https://t.co/IibJiX8UKD
-
-
Mashup Score: 0
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RealâWorld Treatment Patterns and ProgressionâFree Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ NonâSmall Cell Lung Cancer #ALK #TKI #lymphoma #NSCLC #rwPFS https://t.co/KxvM1nyRuE https://t.co/FixApk7dQg
-
-
Mashup Score: 4Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor: - 3 year(s) ago
Abstract Objectives This study quantified the change in blood pressure (BP) during antivascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) therapy, compared BPs between TKIs, …
Source: JACC: CardioOncologyCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Check out a recent paper #JACCCardioOnc Editor-in-Chief Dr. Bonnie Ky referenced on #bloodpressure elevations in the #CardioOnc chat: https://t.co/e4biQf99Ox #TKI https://t.co/7HopdwlRyF
-
-
Mashup Score: 3Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience - 3 year(s) ago
(2020). Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. Leukemia & Lymphoma. Ahead of Print.
Source: Taylor & FrancisCategories: Hem/Oncs, Latest HeadlinesTweet-
Our groupâs report led by Dr Rita Assi @RitaAssi4 & @GCC_Cortes Management of chronic myeloid leukemia during pregnancy among patients treated w/a #TKI : https://t.co/HTrYWh1ixj @garciamanero @GBorthakur @LeukemiaMDA #leusm #endcancer
-
-
Mashup Score: 1Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom? | Haematologica - 3 year(s) ago
Abstract Treatment discontinuation is considered one of the main goals of therapy for patients with chronic myeloid leukemia. Several criteria are felt to be…
Source: haematologica.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The aim of Atallah and Schiffer is to review the results of trials on stopping #TKI in patients with CML and to discuss some clinical and biological questions raised by the observations. https://t.co/81N2pYQ0vJ https://t.co/qgFhSRiac9
-
Clinical and molecular feature-based nomogram for predicting benefit from #bevacizumab combined with first-generation #TKI in #EGFR mutant advanced #NSCLC Read it here: https://t.co/Pa51JAwjpk https://t.co/pKY3CUNBiR